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Introduction
Frontotemporal dementia (FTD) is the second or third most 
common dementia after Alzheimer’s disease (AD), and it com-
prises 3–10% of all neurodegenerative dementias (Yoshiyama 
et al., 2001). 30–50% of persons with FTD have a positive fam-
ily history, and mutations in the microtubule-associated protein 
(MAP) tau are responsible for a large proportion of familial 
FTD cases. Several FTD cases have been linked genetically to 
chromosome 17q21-22 and have been referred to as “fronto-
temporal  dementia  and  parkinsonism  linked  to  chromosome 
17” (Foster et al., 1997). According to a large population-based 
study  in  the  Netherlands,  three  distinct  mutations  (G272V, 
P301L, and R406W) account for 16% of familial FTD cases 
(Rizzu et al., 1999).
Most families with FTDP-17 show deposits of tau in neu-
rons or in glial cells. In some families, the tau deposits are iden-
tical to those present in AD (Spillantini et al., 1996) and consist 
of aggregates of hyperphosphorylated tau proteins in the cell 
soma. Why the MAP tau, which is normally enriched in the 
axon, redistributes to the somatodendritic compartment during 
disease is still a matter of debate. In AD, it has been shown 
that pathologically increased amounts of amyloid  (A), a 
cleavage product of the amyloid precursor protein (APP), trig-
ger an increased phosphorylation of tau (Busciglio et al., 1995; 
Leschik et al., 2007; Tackenberg and Brandt, 2009). Because 
hyperphosphorylated tau exhibits a reduced binding to micro-
tubules, this may result in a loss of tau’s axon-specific localiza-
tion, thus triggering the pathological cascade.
C
hanges of the microtubule-associated protein tau 
are central in Alzheimer’s disease (AD) and fron-
totemporal dementia with Parkinsonism linked to 
chromosome 17 (FTDP-17). However, the functional con-
sequence  of  the  FTDP-17  tau  mutation  R406W,  which 
causes a tauopathy clinically resembling AD, is not well 
understood. We find that the R406W mutation does not 
affect  microtubule  interaction  but  abolishes  tau’s  mem-
brane  binding.  Loss  of  binding  is  associated  with  de-
creased  trapping  at  the  tip  of  neurites  and  increased 
length fluctuations during process growth. Tandem affinity 
purification tag purification and mass spectrometry iden-
tify the calcium-regulated plasma membrane–binding 
protein annexin A2 (AnxA2) as a potential interaction 
partner of tau. Consistently, wild-type tau but not R406W 
tau interacts with AnxA2 in a heterologous yeast ex-
pression system. Sequestration of Ca
2+ or knockdown of 
AnxA2  abolishes  the  differential  trapping  of  wild-type 
and R406W tau. We suggest that the pathological effect 
of the R406W mutation is caused by impaired membrane 
binding,  which  involves  a  functional  interaction  with 
AnxA2 as a membrane–cytoskeleton linker.
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system  isoform  (441  aa)  containing  also  the  adult-specific   
exons 2, 3, and 10 (to allow for an easy reference to previous 
work, the numbering of the mutated site and the phosphoryla-
tion epitopes is based on the tau isoform containing 441 aa). For 
immunological detection and use in live cell imaging, the short 
(8 aa) FLAG-sequence and three longer fluorescent tags (EGFP, 
photoactivatable GFP [PAGFP], and mRFP) were used. The 
tags were fused to the amino termini of the tau variants because 
additional amino-terminal sequences do not interfere with the 
interaction of tau with microtubules or membrane components 
(Brandt et al., 1995; Maas et al., 2000).
The constructs were expressed in PC12 cells as a model 
for neural cells (Fig. 1 A; Greene et al., 1991). In immunoblots 
of lysates of transfected PC12 cells, the proteins separated at 
apparent molecular masses of 50–55 kD and 65–70 kD (FLAG-
tagged 352 and 441 tau, respectively) and 75–80 kD (PAGFP-, 
EGFP-, and mRFP-tagged 352 tau). The electrophoretic mobil-
ity was lower than would be expected from the calculated mo-
lecular weight, which is in agreement with earlier studies (Maas 
et al., 2000; Weissmann et al., 2009). It was evident that wt tau 
separated as a single band, whereas the respective R406W mu-
tated protein separated as a doublet, with one band having a 
higher electrophoretic mobility (Fig. 1 A, right, arrow versus   
arrowhead). This may indicate the presence of a population with 
reduced phosphorylation in R406W tau because it is known that 
phosphorylation leads to detergent-resistant conformational do-
mains in tau protein, which result in decreased electrophoretic 
mobility. Transient or stable expression of the R406W mutant 
did not result in obvious phenotypic alterations of undifferen-
tiated PC12 cells, and comparable amounts of the constructs 
were expressed (Fig. 1 B).
R406W tau exhibits reduced 
phosphorylation at several residues 
compared with wt tau including the PHF1 
site (S396/404), T205, and T212
Tauopathies are thought to be associated with increased phos-
phorylation of tau protein (Stoothoff and Johnson, 2005). How-
ever, with respect to the R406W mutation, both increased and 
decreased phosphorylation of tau have been described depending 
on the cell system used (Krishnamurthy and Johnson, 2004).
To determine the effect of the R406W mutation on the 
phosphorylation profile of tau in PC12 cells, lysates of cells 
that stably expressed FLAG-tagged wt tau or R406W tau were 
analyzed by quantitative immunoblotting with phosphorylation-
sensitive antibodies. As a loading control, blots were also stained 
with the phosphorylation-independent Tau5 antibody, which de-
tects all tau isoforms (Fig. 1 C). Some of the phosphorylation- 
sensitive antibodies (pT205, pT212, pS214, and PHF1) pref-
erentially detected the R406W tau band with the lower elec-
trophoretic mobility (i.e., the upper band), which confirms that 
the reduced electrophoretic mobility of wt tau is caused by a 
higher phosphorylation state. No difference was observed with 
an antibody that detected a dephosphorylated epitope (Tau1). 
The quantification of all immunoreactive bands revealed that 
the R406W mutation exhibits a decreased phosphorylation at 
T205, T212, and the PHF1 epitope (S396/S404; reductions of 
With respect to the underlying molecular mechanism, the 
exonic FTDP-17 mutation R406W is most interesting because it 
causes an early onset tauopathy that clinically closely resembles 
AD and is often misdiagnosed as such (Ostojic et al., 2004; 
Ikeuchi et al., 2008; Lindquist et al., 2008). Why the R406W 
mutation leads to pathological changes in the absence of in-
creased A is unknown.
Overexpression of R406W tau in transgenic mice causes 
age-dependent accumulation of tau aggregates in neuronal peri-
karya, a reduction of the amount of tau in the axon, and in-
duction of neurodegeneration (Zhang et al., 2004). All of these 
features have also been reported in AD mouse models (Götz and 
Ittner, 2008). However, in contrast to hyperphosphorylated tau 
in models of AD, the R406W mutation does not significantly 
alter the ability of tau to regulate microtubule dynamics (Bunker 
et al., 2006). This is consistent with the finding that soluble 
R406W tau from the brain of FTDP-17 patients is not hyper-
phosphorylated but is rather hypophosphorylated as compared 
with tau from healthy subjects (Miyasaka et al., 2001). Several 
studies also found that R406W tau does not differ from wild-
type (wt) tau in its ability to form filaments in vitro (Aoyagi   
et al., 2007; Chang et al., 2008). These findings suggest that 
features other than the perturbation of microtubule binding or 
filament formation are responsible for the redistribution of 
R406W tau to the somatodendritic compartment in the develop-
ment of tau pathology.
We have previously shown that tau binds to the axonal 
membrane cortex through its amino terminal projection domain 
(Brandt et al., 1995). Binding of tau to the membrane was sen-
sitive to phosphorylation and was abolished after experimen-
tal hyperphosphorylation of tau (Maas et al., 2000; Eidenmüller   
et al., 2001). We have also provided evidence that tau is trapped 
in the distal axon mediated by its membrane binding. This trapping 
is abolished in the presence of A or at increased tau phosphory-
lation (Weissmann et al., 2009). It can thus be hypothesized that 
the R406W mutation decreases the interaction of the mutant 
protein with the membrane much like an A-induced tau hyper-
phosphorylation, thereby causing a loss of axonal localization.
To scrutinize functional consequences of the R406W mu-
tation, we expressed epitope-tagged human tau constructs in 
neuronally differentiated PC12 cells. We determined the phos-
phorylation profile using a panel of phosphorylation-sensitive 
antibodies and analyzed tau distribution using fluorescence 
decay after photoactivation. Binding to the membrane cortex was 
determined by subcellular fractionation of surface-biotinylated 
cells, and potential tau interaction partners were identified by 
tandem affinity purification (TAP) tag purification and mass 
spectrometry (MS).
Results
To determine functional consequences of the FTDP-17 mu-
tation R406W in the MAP tau, a panel of epitope-tagged   
human tau variants with or without the R406W mutation in the   
carboxy-terminal nonmicrotubule binding region were produced 
(Fig. 1). The constructs were based on the shortest isoform 
of tau coding for 352 aa and the longest human central nervous   649 R406W mutation blocks tau’s membrane interaction • Gauthier-Kemper et al.
The data indicate that in PC12 cells, R406W tau is less phos-
phorylated at several disease-relevant sites than the wt protein.
The R406W mutation does not affect the 
interaction of tau with microtubules
During tauopathies, tau may change or lose its interaction 
with microtubules, which in turn may affect its distribution 
within neurons.
To assess this interaction for the R406W mutation, we 
transiently  expressed  fluorescently  tagged  tau  constructs  in 
40–65%) as compared with wt tau, whereas other sites were not 
affected or only slightly affected (T181, S199, S214, and S262). 
We did not observe an increased phosphorylation of R406W tau 
at any of the sites analyzed. To determine whether the presence 
of the adult-specific exons affects phosphorylation, quantitative 
immunoblotting was also performed with lysates expressing the 
441 tau isoforms using some of the phosphorylation-sensitive 
antibodies. Again, we did not observe a change with the Tau1 anti-
body, whereas phosphorylation was strongly decreased at T205, 
T212, and the PHF1 epitope (reductions of 40–80%; Fig. 1 D).
Figure 1.  Expression and phosphorylation of human wt and R406W mutated tau in neural PC12 cells. (A) Schematic representation of the epitope-tagged 
tau fusion constructs and immunoblot of tau-expressing cells. The tag is indicated as a green flag, the microtubule-binding region (MBR) as black box. Adult-
specific exons 2, 3, and 10 are indicated in gray. The R406W FTDP-17 mutation and some disease-relevant phosphorylation sites are indicated (numbering 
according to the longest central nervous system tau isoform containing 441 aa). The AT270 antibody recognizes phosphorylated T181, PHF1 phosphory-
lated S396/S404, and Tau1 dephosphorylated S199. Immunoblots of lysates detected with Tau5 antibody show separation of the fusion proteins at the 
expected size. Note that wt tau separates as a single band (arrowhead), whereas R406W mutant tau exhibits a doublet (arrowhead and arrow) indicative 
of the presence of a population with decreased phosphorylation. (B) Fluorescence micrographs of PC12 cells stably expressing different tau constructs 
and a vector control. Proteins were detected using monoclonal anti-FLAG antibody, and nuclei were stained with DAPI. Bar, 10 µm. (C) Immunoblots and 
phosphorylation profile of tau as detected with a panel of phosphorylation-sensitive antibodies. Lysates were prepared from stably transfected FLAG-tau 
(352 tau)-expressing cells. Immunoblots are shown for different phosphorylation-sensitive antibodies as indicated (top) and phosphorylation-insensitive Tau5 
antibody (bottom). Relative immunoreactivity against individual phosphoepitopes was calculated from the total intensities of all tau-reactive bands per lane 
divided by Tau5 immunoreactivity. To plot a phosphorylation profile, the respective values for R406W tau were expressed relative to wt tau, which was set 
as 100%. Mean and range from two independent tau-expressing PC12 cell clones are shown (error bars). 25 µg of protein were loaded per lane. Note the 
decreased phosphorylation of mutant tau at several sites (T205, T212, and S396/404). The amount of endogenous tau was below the detection limit. Black 
lines indicate that intervening lines have been spliced out. (D) Immunoblots and relative immunoreactivity of 441 tau, as detected with a selection from the 
antibodies shown in C. Lysates were prepared from stably transfected Flag-tau (441 tau)-expressing cells. Phosphorylation was decreased at T205, T212, 
and at the PHF1-epitope, similar to 352 tau. Numbers to the sides of the gel blots indicate molecular mass standards in kilodaltons.JCB • VOLUME 192 • NUMBER 4 • 2011   650
The distribution of focally activated PAGFP-tau (PAGFP*-tau) 
was recorded over time (Fig. 3 A). The fluorescence decay in 
the activated region was then plotted against the time, and Deff 
was calculated as described previously using a modeling ap-
proach (Fig. 3 B; Weissmann et al., 2009). We did not find any 
difference in the Deff of wt tau and R406W after coexpression 
with the fluorescence tag (mRFP) alone, which confirms that 
both proteins bind to microtubules to a similar extent (Fig. 3 C). 
The  percentage  of  microtubule-bound  tau  can  be  calculated 
from Df/Deff = 1 + K*, with K* as the ratio of bound/free mol-
ecules (Sprague et al., 2004) and the diffusion coefficient of 
3×PAGFP as a nonbinding control (Df = 6.3 µm
2/s; Weissmann 
et al., 2009). These calculations indicated that the majority of 
wt tau and R406W tau (87% and 88%, respectively) was as-
sociated  with  microtubules  in  the  neurites.  Coexpression  of 
mRFP-labeled tau constructs with PAGFP-tagged tau resulted 
in a decrease of Deff by 40–60%, probably caused by increased 
molecular crowding on the microtubules. We did not observe 
an obvious difference in the Deff of wt tau when coexpressed 
with the same construct or with R406W tau, or of R406W tau 
when coexpressed with the same construct or wt tau. This indi-
cates that wt tau does not displace R406W tau from the surface 
of microtubules, or vice versa, and suggests that both proteins   
interact with microtubules in a very similar manner.
Collectively, the data indicate that the R406W mutation 
does not affect tau-dependent microtubule stabilization or the 
interaction of tau with microtubules in living cells.
R406W tau is deficient in binding to the 
neuronal membrane cortex and exhibits a 
reduced trapping in neurites
We have previously shown that tau interacts with the neural 
membrane cortex in a phosphorylation-dependent manner 
PC12 cells, induced a neuronal phenotype by treatment with 
NGF, and performed a combined fixation–extraction protocol 
to visualize microtubule-associated tau protein (Fig. 2 A, left). 
We observed that wt tau and R406W tau exhibited a very similar 
filamentous staining pattern indicative of binding to microtubules. 
Both proteins were enriched in neurites and were also present in 
filamentous structures in growth cones (Fig. 2 A, left, arrowheads 
and insets). When wt tau and R406W tau were coexpressed in 
the same cell, no difference in the distribution was observed, as 
indicated by the yellow color in the overlay (Fig. 2 A, right). 
This suggests that both wt tau and R406W tau bind to the same 
microtubule subpopulations in NGF-differentiated PC12 cells.
It is known that binding of tau to microtubules results in 
increased microtubule stability, which is manifested by a higher 
ratio of acetylated/total tubulin (Piperno et al., 1987). To deter-
mine the degree of microtubule stabilization, lysates from cells 
that stably expressed FLAG-tagged wt tau and R406W tau were 
analyzed by immunoblotting and compared with control cells. 
Immunodetection used antibodies against tau, acetylated tubu-
lin, and total -tubulin (Fig. 2 B, left). Quantification revealed 
that wt tau and R406W tau expression led to an 30% increase 
in microtubule stability as compared with control cells (Fig. 2 B, 
right). No difference was observed between wt tau and R406W 
tau–expressing cells, again indicating that both proteins bind 
to the same extent to microtubules. Thus, the data indicate that 
despite its decreased phosphorylation, R406W tau does not en-
hance microtubule stabilization.
It is possible that wt tau and R406W tau bind in a differ-
ent manner to microtubules, which could for example result in a 
displacement of mutant tau by wt tau from microtubules. To ex-
plore this hypothesis, we determined the effective diffusion co-
efficient (Deff) of PAGFP-tau in neurites when coexpressed with 
mRFP-wt tau, mRFP-R406W tau, or the fluorescence tag alone. 
Figure 2.  Fluorescent-tagged wt and R406W   
tau interact similarly with microtubules. (A) Fluor-
escence micrographs (left) and double fluor-
escence images (right) of detergent-extracted 
cells expressing the indicated tau constructs. 
The growth cone region is shown enlarged in 
the insets. Note the filamentous staining pat-
terns in the growth cone regions (arrowheads) 
indicative of cytoskeletal association (left). Co-
localization of wt tau and R406W tau suggests 
binding to the same subpopulation of microtu-
bules (right). Bars, 20 µm. (B) Immunodetection 
of tau, acetylated tubulin (ac-tub), and total   
-tubulin  of  lysates  from  tau-expressing  and 
vector-control PC12 cell lines. Indicated amounts 
of protein were loaded per lane. Relative im-
munoreactivity  of  the  ac-tub  signal  to  total   
-tubulin was calculated from the lanes where 
10 µg of protein had been separated. Note 
the increased ratios of acetylated to total tu-
bulin in human tau-expressing cells compared 
with  control  lines  indicative  of  microtubule 
stabilization. No difference was observed be-
tween wt and R406W tau–expressing cells. 
Mean and range from two independent tau-
expressing PC12 cell clones are shown (error 
bars). Experiments were performed with the 
352 tau isoform. Numbers to the sides of the 
gel blots indicate molecular mass standards 
in kilodaltons.651 R406W mutation blocks tau’s membrane interaction • Gauthier-Kemper et al.
R406W tau and wt tau, respectively). This suggests that the 
nonplasma membrane-bound R406W tau is instead present in 
the cytosol. Thus, the data suggest that the R406W mutation 
abolishes tau’s association with the membrane cortex and in-
creases the amount of tau in the cytosolic fraction.
To determine whether the difference in membrane binding 
can also be visualized by fluorescence microscopy, we followed 
tau distribution after focal activation of tau. In fact, PAGFP*-wt 
tau showed a clear enrichment at the periphery, which suggests 
its membrane association, whereas PAGFP*-R406W tau exhib-
ited a uniform distribution within the process (Fig. 4 C). To de-
termine whether the difference in membrane binding affects 
trapping of tau in neurites, we photoactivated wt tau and R406W 
tau in the tip of a neurite and followed its distribution over time. 
It was evident from the color-coded plots of 2D intensity func-
tions that PAGFP*-R406W dissipated faster from the activation 
spot than PAGFP*-wt tau (Fig. 5 A). For quantification of the 
extent of trapping, the fraction of tau in the activated spot was 
compared with total tau (It/Itot) at different time points after acti-
vation. We observed that It/Itot was significantly higher for wt 
tau as compared with R406W tau (Fig. 5 B). This indicates a 
preferential trapping of wt tau in agreement with its ability to 
interact with the plasma membrane. We determined the effective 
(Brandt et al., 1995; Maas et al., 2000). Tau’s association with 
the membrane cortex may play an important role in the axonal 
localization of tau and may contribute to the trapping of tau in 
distal processes (Weissmann et al., 2009).
To determine whether the R406W mutation affects the as-
sociation of tau with the membrane cortex, cell fractionations 
were used to enrich plasma membranes and proteins of the as-
sociated membrane cortex (PM fraction). The protocol is based 
on magnetic sphere separation of surface-biotinylated cells that 
were  homogenized  at  mild  conditions  (Fig.  4 A). With  this 
method, a PM fraction, which contains 30–35% of the total 
cellular actin, is obtained, indicating the presence of the actin-
rich membrane cortex. This fraction is devoid of tubulin, which 
behaves as a soluble cytosolic protein under the conditions of frac-
tionation (Fig. 4 B). In agreement with previous results (Maas 
et al., 2000), 20–30% of total wt tau was present in the PM 
fraction as detected with antibodies against total tau (Tau5) and 
a dephosphorylated tau epitope (Tau1). In contrast to wt tau, 
R406W tau was completely absent from the PM fraction. Quan-
tification of the Tau5 blot revealed that the percentage of the tau 
signal in the organelle/membrane fraction was similar for R406W 
tau and wt tau (27% and 22%, respectively), whereas the percent-
age of cytosolic R406W tau was much higher (73% and 52% for 
Figure  3.  Wt  and  R406W  tau  exhibit 
same effective diffusion in the neuritic shaft.  
(A) Live cell imaging of a PC12 cell coexpress-
ing  mRFP-tagged  wt  tau  and  PAGFP-tagged 
R406W tau after fluorescence photoactivation. 
The position of photoactivation is indicated by 
a circle in the preactivation images, and distri-
bution between 1 and 112 s was determined. 
Fluorescence decay of PAGFP-R406W tau in 
the activated region as a result of diffusion is 
marked by the arrows. Bar, 20 µm. (B) Fits of 
representative decay plots to model diffusion 
of PAGFP-wt tau and R406W tau. Modeling 
was performed as described in Materials and 
methods.  (C)  Effective  diffusion  coefficients 
for  PAGFP-tau  in  different  combinations  of 
coexpression.  Stably  transfected  PAGFP-tau– 
expressing  lines  were  transiently  transfected 
with mRFP or mRFP-tagged constructs as indi-
cated. Coexpression of tau constructs reduces 
the diffusion similarly for wt and R406W tau. 
Values are shown as mean ± SEM from fits of 
n processes. Experiments were performed with 
the 352 tau isoform.JCB • VOLUME 192 • NUMBER 4 • 2011   652
Figure 4.  R406W tau is deficient in binding to the neural plasma membrane. (A) Schematic representation of the plasma membrane fractionation assay to   
analyze tau’s interaction with the neural membrane cortex. (B) Immunoblot showing the distribution of FLAG-tagged tau, actin, and tubulin in the cytosolic (Cyt), 
organelles/membrane (OM), and plasma membrane/membrane cortex (PM) fractions. Note the complete absence of R406W tau mutant in the PM 
fraction, whereas a major amount of wt tau is PM-associated. Numbers to the sides of the gel blots indicate molecular mass standards in kilodaltons.   
(C) Time-lapse microscopic images of processes from PC12 cells expressing PAGFP-tagged tau constructs after photoactivation. A close-up of the processes 
(red box) is shown and the position of photoactivation is indicated by a circle. Note the enrichment of wt tau close to the plasma membrane (arrows), 
whereas R406W tau shows a uniform distribution. Experiments were performed with the 352 tau isoform. Bar, 10 µm.653 R406W mutation blocks tau’s membrane interaction • Gauthier-Kemper et al.
Unfortunately, the presence of Ca
2+ resulted in the precipitation 
of AnxA2 even at control conditions (PAGFP alone; unpub-
lished data), probably because of the formation of unspecific 
complexes in the presence of neural membrane components. 
To overcome this limitation, we coexpressed human tau with 
GFP-tagged human AnxA2 in the heterologous yeast system. 
The proteins were clearly produced and present in crude ex-
tracts (Fig. 7 B, input). In pull-down assays in the presence of 
Ca
2+, between 25 and 40% wt tau coprecipitated with AnxA2, 
whereas R406W tau remained completely in the supernatant 
(Fig. 7 B, top). Copreciptation occurred with both the 352 and 
diffusion constants for wt and R406W tau after activation in the 
tip by taking into account that diffusion is restricted to one di-
rection. Deff in the tip was less than half for wt tau compared 
with R406W tau (Fig. 5 C) and compared with the diffusion of 
tau in the shaft (see Fig. 3). The data suggest that tau’s mem-
brane association causes retention of tau in the tip of neurites, 
which is compromised by the R406W mutation.
The R406W mutation causes fluctuations 
during process outgrowth
The data presented indicate that wt tau and R406W tau differ 
in their ability to interact with membranes in the processes of 
neural cells. Consequently, the loss of membrane interaction as a 
result of the R406W mutation could also affect neurite extension.
To  test  whether  tau’s  membrane  interaction  influences 
process extension in differentiating PC12 cells, process growth 
was followed by live cell imaging of NGF-treated PC12 cells, 
which stably expressed EGFP-tagged wt tau or R406W tau. We 
observed that processes of cells expressing wt tau appeared to 
continuously extend their length with time in culture (Fig. 6 A, 
top; and Fig. 6 B, left). In contrast, processes from R406W tau– 
expressing cells showed large fluctuations between elongating 
and shrinking states (Fig. 6 A, bottom; and Fig. 6 B, right). Quan-
tification confirmed that R406W tau–expressing cells exhibited 
larger length changes during process growth compared with wt 
tau–expressing or EGFP-expressing control cells (Fig. 6 C).   
The total length of the processes did not differ between cells 
expressing the two tau constructs, as determined from popula-
tion analysis after 6 d of NGF treatment (Fig. 6 D). The data 
indicate that the R406W mutation induces larger fluctuations 
in elongation rates, which suggests that tau’s membrane inter-
action stabilizes process growth.
The plasma membrane–associated protein 
annexin A2 (AnxA2) functionally interacts 
with tau to mediate trapping in neurites
Because the wt protein associates with the membrane cortex, 
in contrast to R406W tau, we performed TAP tag MS of tau- 
transfected neural cells to identify membranous or membrane-
associated proteins as potential tau interaction partners. To 
solubilize the membrane, lysates were prepared at low deter-
gent concentrations (0.15% NP-40). With this approach, the 
calcium-regulated  membrane  and  microfilament-interacting 
protein AnxA2 was identified as a prominent component of a 
tau-containing complex (Fig. 7 A). To test for a direct inter-
action  between  tau  and  AnxA2,  we  performed  yeast  two- 
hybrid experiments with human wt tau, R406W tau, and human   
AnxA2. None of the tested combinations displayed any inter-
action (unpublished data). Thus, either tau and AnxA2 do not 
directly interact, or the interaction may not occur within the yeast 
nuclear environment (e.g., because of the absence of suitable mem-
brane components or an inappropriate Ca
2+ concentration). To test 
for interaction of AnxA2 and tau in PC12 cells, cellular lysates 
were prepared and PAGFP-tau was precipitated using a GFP-
trap in the presence of NP-40. We did not detect endogenous 
AnxA2 coprecipitating with human tau when the experiments 
were performed in the absence of Ca
2+ (unpublished data). 
Figure 5.  R406W tau exhibits reduced trapping in the tip of neurites com-
pared with wt tau. (A) Contour and color-coded plots of 2D intensity func-
tions after photoactivation in the tip of representative processes expressing 
PAGFP wt and R406W tau. Position of activation is indicated by black 
arrowheads in the contour plot. Fluorescence intensity is color-coded from 
blue to red as indicated on the right. Note that the dissipation of fluores-
cence in the activated region occurs faster with R406W tau compared 
with wt tau. (B) Quantification of retention after focal activation of wt and 
R406W tau in the tip of neurites. Immobile fractions at different time points 
after activation (It/Itot) show decreased retention of R406W compared with 
wt tau. Values are shown as mean ± SEM (error bars). **, P < 0.01;   
*, P < 0.05 (n = 12–21). (C) Effective diffusion coefficients of tau after photo-
activation at the tip of processes in PC12 cells stably expressing PAGFP 
wt tau or R406W tau. Values are shown as mean ± SEM with fits from   
n cells. Note the decreased Deff value corresponding to the increased reten-
tion of wt tau compared with R406W tau. Experiments were performed 
with the 352 tau isoform.JCB • VOLUME 192 • NUMBER 4 • 2011   654
expressed wt tau or R406W tau were infected with lentivirus en-
coding AnxA2 shRNA or a control shRNA. Infected cells were 
selected with puromycin. Western blot analysis showed that the 
amount of AnxA2 strongly decreased to 21.7 ± 5.5% (n = 4) with 
AnxA2  shRNA,  whereas  only  minor  changes  were  observed 
when the cells were treated with the control shRNA (Fig. 9 A). 
Consequently, a strong reduction of annexin staining was also 
observed by immunocytochemistry (Fig. 9 B). It should be noted 
that tau levels were approximately twice as high in cells that 
have been treated with AnxA2 shRNA compared with untreated 
cells. We also observed that treatment with the control shRNA 
increased the amount of tau to a similar extent, which indicates 
that the changes in tau expression are related to the puromycin 
treatment during the selection and not to AnxA2 knockdown.
The effect of AnxA2 knockdown on tau trapping was then 
analyzed after photoactivation of tau in the tip of neurites. We ob-
served that the difference in the retention of wt tau and R406W 
tau was abolished after annexin knockdown (Fig. 9 C). In agree-
ment, Deff in the tip was much lower for wt tau compared with 
R406W tau after infection with the control shRNA, whereas it 
was similar in AnxA2 shRNA–treated cells (Fig. 9 C, right).
Because it is known that binding of AnxA2 to membranes 
requires calcium (Gerke and Moss, 2002; Gerke et al., 2005), 
we treated cells expressing wt tau or R406W tau (in the absence 
the 441 wt tau isoform, indicating that the additional exons were   
not required for the interaction with AnxA2. In control experi-
ments where GFP was coexpressed with the tau constructs, neither   
352 nor 441 tau precipitated. Thus, the data indicate that in a   
heterologous yeast system, AnxA2 and tau specifically interact.
To test whether tau and annexin could also interact in 
neural cells, we performed colocalization experiments in differ-
entiated PC12 cells and primary cortical cultures. Endogenous 
AnxA2 was present in the cell body and in processes, where 
it showed enrichment in distal tips (Fig. 8 A). Transfected tau 
was also present in the cell body, the neurites, and the tip of 
processes. In growth cones, we observed colocalization of tau 
and AnxA2 in filamentous structures (Fig. 8 A, insets), which 
is consistent with a tau–annexin interaction in this region. To 
test for interaction with cytoskeletal structures, we performed a 
combined fixation–extraction protocol. We observed that a sig-
nificant amount of AnxA2 was retained together with tau in the 
cell body, neurites of differentiated PC12 cells (Fig. 8 B), and 
axons of primary cortical cultures (Fig. 8 C), confirming that 
tau and AnxA2 are present in the same compartment and associ-
ate with cytoskeletal structures.
To test for a functional interaction between tau and annexin 
in neurites, we knocked down AnxA2 in PC12 cells by small 
hairpin RNA (shRNA). For these experiments, cells that stably 
Figure 6.  The R406W mutation induces higher fluctuations during process growth. (A) Live imaging of PC12 cells stably expressing EGFP-tagged wt tau and 
R406W tau. Fluorescence micrographs of the same cell at different times after induction of differentiation with NGF are shown. Two representative processes 
per cell are followed over time and are indicated by arrowheads. Bar, 100 µm. (B) Plot of the lengths of the representative processes indicated in A over 
time. Note that the processes of the R406W tau–expressing cell showed large fluctuations in lengths over time. (C) Quantification of mean length change per 
day for tau-expressing cells compared with an EGFP-expressing control (con). Results are shown as mean ± SEM (error bars). ***, P < 0.001; *, P < 0.05 
compared with the EGFP-expressing control (n = 52–81 processes). Two independent clonal lines were used per construct. (D) Mean length of processes after 
6 d of NGF treatment as determined by population analysis. 23–31 of processes were measured for the respective cell lines. Mean process lengths ± SEM 
are given (error bars). Note that the overall process length is similar for tau-expressing cells. Experiments were performed with the 352 tau isoform.655 R406W mutation blocks tau’s membrane interaction • Gauthier-Kemper et al.
Collectively, the data indicate that wt tau but not R406W 
tau functionally interact with AnxA2 in neural growth cones 
and suggest that this interaction regulates the distribution of 
both proteins.
Discussion
We have shown that the R406W FTD tau mutation abolishes the 
ability of tau to interact with the neural membrane cortex and 
reduces trapping of tau in the tip of neuron-like processes. In 
contrast, microtubule-related features such as the activity to sta-
bilize microtubules or the extent and dynamics of microtubule 
binding in neuronal processes were unaffected by the mutation. 
Previously, it had been shown that some FTDP-17 mutations 
compromised tau’s ability to affect microtubule dynamics, 
whereas the R406W mutation did not alter microtubule-related 
activities (Bunker et al., 2006) and was indistinguishable in the 
colocalization pattern with microtubules (DeTure et al., 2000). 
This is consistent with the idea that at least some FTDP-17 
mutations affect other activities of tau rather than binding to 
microtubules. It will be interesting to determine whether other 
tau mutations that have been frequently observed in FTDP-17 
cases such as G272V and P301L also influence tau’s interaction 
with annexin.
of shRNA) with the cell-permeable calcium chelator BAPTA/AM   
to interfere with the annexin–membrane interaction. Also,   
after BAPTA treatment, the difference in the retention of 
wt tau and R406W tau was abolished (Fig. 9 D), which again sug-
gests that tau trapping is caused by an interaction with AnxA2 
at the membrane.
If AnxA2 causes retention of wt tau due to a functional 
interaction in the tip of processes, it may be expected that, in 
turn, wt tau expression reduces the mobility of AnxA2 in growth 
cones. To test this hypothesis, we prepared an AnxA2–PAGFP 
fusion construct and expressed it in PC12 cells. An immunoblot 
of cellular lysates confirmed that the full-length construct was 
expressed in infected cells in addition to endogenous annexin 
(Fig. 10 A). We observed that AnxA2–PAGFP was distributed in 
the cytosol and the processes and showed an enrichment at the 
tip of neurites similar to endogenous AnxA2 (Fig. 10 B, compare 
with Fig. 8 A). Wt tau colocalized with AnxA2–PAGFP at the 
tip while R406W tau was absent. To test whether tau expression 
affects the mobility of AnxA2, we performed fluorescence decay 
after photoactivation experiments where AnxA2–PAGFP was ac-
tivated at the tip of the processes and its dissipation followed over 
time. We observed that wt tau expression caused an increased 
retention of AnxA2–PAGFP* in the tip compared with R406W 
tau–expressing or untransfected control cells (Fig. 10 C).
Figure 7.  Identification of annexinA2 as a putative tau interaction partner. (A) TAP of tau protein. Amino-terminally TAP-tagged 441 tau was purified from 
SKNBE2 cells, separated by SDS-PAGE, and stained with colloidal Coomassie. The overexpressed tau protein is clearly visible at an apparent molecular 
mass of 70–80 kD. Copurifying proteins identified by LC-MS/MS are labeled. The sequence coverage for the AnxA2 protein sequence was 23% (indi-
cated by marking sequenced peptides underlined and in boldface). (B) Pull-down of GFP-tagged Anx A2 fusion constructs in yeast. Wt tau coprecipitated 
after pull-down of GFP–Anx A2. No coprecipitation of R406W tau was observed. In control experiments (pull-down of GFP), wt tau did not coprecipitate. 
Numbers to the sides of the gel blots indicate molecular mass standards in kilodaltons.JCB • VOLUME 192 • NUMBER 4 • 2011   656
R406W mutation exerts long-range conformational effects 
on the structure of tau (Connell et al., 2001), which could ex-
plain an effect of the carboxy-terminal mutation on the amino- 
terminal domain. This is also consistent with the reduced phos-
phorylation of T205 and T212 in R406W tau compared with 
wt tau, residues that are both located in the amino-terminal 
half of the protein. Previously, we have observed similar and 
selective long-range effects when we analyzed the influence of 
phosphorylation on tau’s ability to interact with the membrane 
cortex. We found that pseudophosphorylation in tau’s carboxy 
terminus abolished tau’s interaction with the membrane cortex, 
whereas tau’s ability to promote microtubule assembly was un-
changed (Eidenmüller et al., 2001).
What is the functional role of tau’s interaction with the 
membrane? We previously demonstrated that overexpression of 
tau’s amino terminus inhibits process outgrowth in cells (Brandt 
et al., 1995), and suggested that tau’s membrane interaction 
supports process formation that is competitively suppressed by 
the amino-terminal fragment. Consistent with this hypothesis, 
we have found here that R406W tau–expressing cells showed 
higher fluctuations in process extension compared with wt tau, 
which may suggest that tau’s membrane interaction supports 
stable  process  growth,  presumably  by  bridging  the  growing 
microtubules to the membrane cortex in the growth cone. Our 
data suggest that this bridging is mediated by AnxA2 (see the 
following paragraph). It has been reported that AnxA2 is up-
regulated  during  NGF-induced  differentiation  of  PC12  cells 
(Schlaepfer and Haigler, 1990; Fox et al., 1991), which parallels 
The R406W mutation reduced rather than increased phos-
phorylation at several positions, including the PHF1 epitope 
(S396/S404), T212, and T205. Decreased phosphorylation of 
R406W tau at several sites has also been reported earlier in dif-
ferent cellular systems (Dayanandan et al., 1999; Matsumura 
et al., 1999; Vogelsberg-Ragaglia et al., 2000; DeTure et al., 
2002;  Tackenberg  and  Brandt,  2009). Among  others,  all  of 
these sites can be phosphorylated in vitro by the kinases Cdk5 
and GSK3, both of which have been implicated as having 
a role in AD (Cruz and Tsai, 2004; Hooper et al., 2008). The 
data presented here also indicate that phosphorylation at these 
positions does not affect tau’s ability to stabilize microtubules. 
This is in agreement with the finding that the extent of phos-
phorylation at Ser262, which is located within the microtubule-
binding region and known to critically affect tau’s microtubule 
interaction (Biernat et al., 1993), was not significantly changed 
in the R406W variant. However, it is possible that the changes 
in the phosphorylation profile that are induced by the R406W 
mutation induce more subtle changes with respect to tau’s   
microtubule-related activities.
On  first  view,  it  appears  surprising  that  a  mutation  in 
tau’s carboxy-terminal region selectively affects a feature that 
is known to be mediated by the opposite side of the molecule, 
the amino-terminal projection domain of tau. However, it has 
been shown previously that tau can adopt a “paperclip” con-
formation, in which the amino- and carboxy-terminal domains 
approach  each  other  (Jeganathan  et  al.,  2006).  Furthermore, 
MS analysis of the phosphorylation pattern suggested that the 
Figure 8.  Distribution of tau and AnxA2 in PC12 cells and primary cortical neurons. (A) Fluorescence micrographs of neuronally differentiated PC12 
cells stably expressing PAGFP wt tau. Cells were fixed with paraformaldehyde and stained against GFP and endogenous AnxA2. The growth cone 
region is shown enlarged in the insets. Note the enrichment of AnxA2 at the tip of processes and colocalization of tau and AnxA2 in filamentous 
structures of the growth cone (arrowheads). (B and C) Fluorescence micrographs of PC12 cells stably expressing PAGFP wt tau (B) and primary cortical 
neurons (C) after a combined detergent extraction–fixation protocol to reveal cytoskeletal association. PC12 cells were stained against GFP and endog-
enous AnxA2, and cortical neurons were stained against endogenous tau and AnxA2. Note that a significant amount of AnxA2 is retained together 
with tau in the cell body and neurites of PC12 cells, as well as the axons of primary neurons. Experiments were performed with the 352 tau isoform.   
Bars: (A and B) 10 µm; (C) 50 µm.657 R406W mutation blocks tau’s membrane interaction • Gauthier-Kemper et al.
Figure 9.  Annexin A2 is required for trapping of wt tau in the tip of neurites. (A) Immunoblots demonstrating shRNA-mediated knockdown of AnxA2 in 
PC12 cells. PC12 cells stably expressing PAGFP wt tau or R406W tau were infected with lentiviral particles coding for AnxA2 shRNA (AnxA2 shRNA) or a 
control shRNA (con shRNA). Infected cells were selected with puromycin as described in Materials and methods. Annexin A2 protein is reduced by 80% in 
AnxA2 shRNA-treated cells. (B) Immunofluorescence images of PC12 cells stably expressing PAGFP wt tau and R406W tau with or without shRNA-mediated 
annexin knockdown. Staining was against AnxA2 and the GFP tag. After knockdown, AnxA2 is hardly detectable by immunofluorescence. Bar, 10 µm.   
(C) Retention of wt tau and R406W tau in the tip of processes after treatment with control shRNA and after shRNA-mediated AnxA2 knockdown. Immobile 
fractions after activation (It/Itot) were determined after 10 s and expressed relative to wt tau. Values are shown as mean ± SEM (error bars); *, P < 0.05 
(n = 10–16). Effective diffusion coefficients of the respective experiments are shown in the table. Values are shown as mean ± SEM with fits from n cells. 
Note that annexin knockdown abolished the difference in retention and Deff values between wt tau and R406W tau. (D) Retention of wt tau and R406W 
tau in the tip of processes in the presence of the calcium chelator BAPTA/AM (BAPTA). Immobile fractions were determined as described in C. Note that 
the different retention of wt tau and R406W tau is abolished in the presence of BAPTA. Values are shown as mean ± SEM (error bars; n = 11–16). Experi-
ments were performed with the 352 tau isoform.JCB • VOLUME 192 • NUMBER 4 • 2011   658
determined by differential intracellular calcium concentrations 
in the cell (Gerke and Moss, 1997). Ca
2+-regulated membrane 
binding of AnxA2 could also provide a mechanism to localize 
tau in an activity-dependent manner to the presynaptic region, 
thus regulating microtubule dynamics in parallel to the firing 
of a synapse.
Mice lacking AnxA2 show no obvious phenotypic change. 
Therefore, it has been proposed that other annexins can com-
pensate for a functional loss of AnxA2 in a knockout scenario 
(Rescher and Gerke, 2004). Thus, transient down-regulation by 
RNA interference or expression of dominant interfering mutants 
may be more informative to analyze AnxA2-mediated activities. 
In fact, we observed that lentiviral shRNA administration caused 
a transient decrease of AnxA2 in cells and affected the trapping 
of tau in neuronal processes. In contrast, long-term expression of 
shRNA did not result in a decrease of AnxA2 protein, probably 
because of compensating mechanisms (unpublished data).
Our observation that the R406W mutation reduces trap-
ping of tau in the distal neurite, which is probably caused by its 
decreased interaction with AnxA2, could be relevant in a neuro-
degenerative scenario. Decreased binding of R406W tau could 
result in a reduced stability of the presynapse and a distribution 
of tau R406W, which is less confined to the distal process. In 
this context, it appears remarkable that both A-mediated   
hyperphosphorylation of tau in an AD scenario and the R406W 
mutation converge with respect to a loss of function of tau to   
interact with the plasma membrane. This could provide an ex-
planation as to why the R406W tau mutation produces a pheno-
type that is clinically closely related to AD. Interestingly, in 
pathological conditions including seizures and AD, AnxA2 ex-
pression is increased (Eberhard et al., 1994). This could point to 
a compensatory mechanism of affected neurons in an attempt to 
rescue tau’s membrane interaction in such patients.
the increased expression of tau (Drubin et al., 1988). This would 
be consistent with an involvement of both proteins in regulating 
neurite outgrowth (Fox et al., 1991; Jacovina et al., 2001). Very 
recently, it has been reported that tau affects neurite initiation 
without requirement for microtubule binding (Leugers and Lee, 
2010). It is conceivable that tau’s association with the mem-
brane cortex is also involved in this activity.
Several lines of evidence reported here support the find-
ing that tau interacts with AnxA2. (a) Annexin A2 was identi-
fied as an interacting protein using a TAP tag approach with tau 
as a bait. (b) Tau coprecipitated with AnxA2 in a heterologous 
yeast expression system. (c) Tau and AnxA2 colocalized in 
neuronally differentiated cells, and we observed colocalization 
of tau and AnxA2 in filamentous structures in the growth cones. 
(d) shRNA-mediated AnxA2 knockdown abolished trapping of 
tau in the tip of neurites. (e) Chelation of Ca
2+ ions by treatment 
with BAPTA/AM, which is known to remove annexin from the 
plasma membrane, increases the mobility of tau in the tip of 
neurites. (f) Expression of tau increases the retention of AnxA2 
in distal processes. Annexins are a multigene family of calcium-
regulated membrane-binding proteins, which are expressed in 
most eukaryotic cell types and species (Gerke and Moss, 2002). 
In vertebrates, 12 subfamilies are expressed, termed A1–11 and 
A13 (Morgan and Fernández, 1997). The annexins share a core 
domain, which serves as a general membrane-binding module 
consisting  of  four  -helical  annexin  repeats  and  an  amino- 
terminal head region of various lengths, which extends into 
the cytosol (Rescher and Gerke, 2004). Annexin A2 is mainly 
localized at the plasma membrane and the N-terminal domain 
modulates  its  membrane  binding  activity  (Gerke  and  Moss, 
2002). Plasma membrane binding is reversible and chelation 
of calcium results in liberation of AnxA2 from the membrane. 
Thus,  the  localization  and  distribution  of AnxA2  may  be   
Figure 10.  Tau expression reduces the mobility of AnxA2 in growth cones. (A) Immunoblot showing the expression of PAGFP-tagged AnxA2 at the ex-
pected size (arrows). Endogenous annexin is indicated by the arrowhead. Tubulin is stained as loading control. (B) Fluorescence micrographs of PC12 cells 
stably expressing FLAG-tagged wt tau or R406W tau after infection with a lentivirus encoding AnxA2–PAGFP. Cells were fixed with paraformaldehyde and 
stained with antibodies against GFP (for AnxA2–PAGFP) and the FLAG-epitope (for tau). Close-ups of the tips of processes are shown on the right. Note that 
AnxA2–PAGFP showed an enrichment at the tip of neurites similar to endogenous AnxA2. Wt tau colocalized with AnxA2–PAGFP at the tip while R406W 
tau was absent (arrowheads). Bar, 10 µm. (C) Retention of AnxA2–PAGFP at the tip of neuronally differentiated PC12 cells stably expressing FLAG-tagged 
wt tau, R406W tau, or control cells. Note the increased retention of AnxA2–PAGFP* in wt tau, but not in R406W tau–expressing cells or control cells. 
Values are shown as mean ± SEM (error bars). ***, P < 0.001; *, P < 0.05 (n = 6–27). Experiments were performed with the 352 tau isoform.659 R406W mutation blocks tau’s membrane interaction • Gauthier-Kemper et al.
objective lens on a fluorescence microscope (Eclipse TE2000-U; Nikon) 
equipped with a digital camera (COOL-1300; Vosskühler). Image analysis 
used the program Lucia G version 4.60 (Nikon).
Photoactivation and live imaging
Live  imaging  was  performed  on  a  laser  scanning  microscope  (Eclipse 
TE2000-U inverted; Nikon) equipped with argon (488 nm), helium/neon   
(543 nm) and blue diode (405 nm) lasers. PAGFP-expressing cells were visual-
ized with a Fluor 60× (NA 1.4) UV-corrected (VC) objective lens. The micro-
scope was enclosed in an incubation chamber maintained at 37°C and 5% 
CO2 (Solent Scientific Limited). Automated image acquisition after photo-
activation was essentially performed as described previously (Weissmann   
et al., 2009). Photoactivation was performed with the blue diode producing 
an activation spot 5 µm in diameter. Frames were obtained at a frequency 
of 1 frame/s or 1 frame/12 s, and 112 frames were collected per experi-
ment. Standard series were collected at a resolution of 256 × 256 pixels. 
For higher resolution imaging, images were collected at 512 × 512 pixels 
with a frame frequency of one frame every 3 s. Live cell imaging of EGFP-
expressing cell lines was performed by acquiring images of single cells at a 
resolution of 512 × 512 pixels at 488 nm. Cells were relocated at different 
days with the help of gridded incubation chambers. Determination of process 
numbers and length was performed using EZ-C1 software (Nikon).
Image analysis and modeling
Image analysis of photoactivation experiments was performed essentially 
as described previously (Weissmann et al., 2009). To provide a visual rep-
resentation of the distribution over time, data were plotted as a color-coded 
filled contour plot of 2D intensity function. To compare the distribution of 
different constructs, It/Itot from the fluorescence intensity at time t after acti-
vation  in  the  activated  segment  and  the  fluorescence  signal  from  total 
photoactivation were determined. This value reflects the immobile fraction 
of the activated population in the activated segment at time t. Effective dif-
fusion coefficients were determined by using a diffusion model solving 
Fick’s second diffusion equation and fitting the data from the photoactiva-
tion experiments as described previously (Weissmann et al., 2009).
shRNA treatment of cultures
PC12 cells stably expressing PAGFP-wt tau or R406W tau were plated on 
35-mm dishes. After 24 h, medium was exchanged to serum-DME contain-
ing 5 µg/ml hexadimethrine bromide to neutralize charge interactions and 
to increase binding between the pseudoviral capsid and the cellular mem-
brane. Lentiviral particles coding for AnxA2 shRNA or a scrambled shRNA 
sequence as a control (Santa Cruz Biotechnology, Inc.) were thawed at 
room temperature, gently mixed before use, and added to the culture. 
After overnight exposure at 37°C and 5% CO2, medium was exchanged 
against serum-DME. Tau-expressing stable lines were additionally treated 
with 250 µg/ml Geneticin. To select stable clones expressing the AnxA2 
shRNA or the control shRNA, cells were split on the next day 1:4 and 
incubated for another 24 h in serum-DME. Selection was performed with 
5 µg/ml puromycin dihydrochloride (Acros Organics). Medium was re-
placed with fresh Geneticin- and puromycin-containing medium every 3–4 d. 
6 d after infection, NGF treatment with 100 ng/ml 7S mouse NGF was 
started and continued for 4 d. Cells were analyzed 10 d after infection. 
For immunoblotting, cell lysate was prepared in RIPA buffer (50 mM Tris-
HCl, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.5% deoxycholate, and 
0.1% SDS, pH 8.0) containing protease inhibitors (1 mM PMSF, 10 µg/ml 
leupeptin, 10 µg/ml pepstatin, and 1 mM EGTA).
Microsphere separation of the membrane cortex
Microsphere separation of the neural membrane cortex was performed 
from PC12 cells stably expressing wt tau or R406W tau as described 
previously (Maas et al., 2000). PC12 cells stably transfected with FLAG-wt 
tau or FLAG-R406W tau were surface labeled with sulfosuccinimidyl 
2-(biotinamido)ethyl-1,3-dithiopropionate (Pierce) and incubated with 
streptavidin-coated microspheres. Cellular homogenates were prepared by 
freeze-thawing the scraped-off cells in a separation buffer (0.25 M sucrose 
containing 1 mM ATP, 1 mM MgCl2, 1 mM EGTA, and protease and phos-
phatase inhibitors), and the plasma membrane/membrane cortex fraction 
(PM) was separated with a magnetic bead attractor. The unbound material 
was separated by ultracentrifugation into an organelle/membrane pellet 
and a cytosol fraction (Fig. 4 A).
TAP and mass spectrometric analyses
A tau expression vector was generated by site-specific recombination 
(Gateway; Invitrogen) of the PCR-amplified 441 tau open reading frame 
into  the  MoMLV-based  vector  pZome1  (Cellzome;  Euroscarf  GmbH). 
Materials and methods
Materials and antibodies
Chemicals were obtained from Sigma-Aldrich, cell culture media and supple-
ments were obtained from Sigma-Aldrich and Invitrogen, and culture flasks, 
plates, and dishes from were obtained from Thermo Fisher Scientific, unless 
stated otherwise. The following antibodies were used. Phosphorylation- 
independent human tau antibodies: Tau-5 (mouse; BD) and anti-tau (rabbit; 
Synaptic  Systems  GmbH).  Phosphorylation-dependent  tau  antibodies: 
AT270 (Thr-181, mouse; Pierce), pT205 (Thr-205, rabbit; Invitrogen), 
pT212 (Thr-212, rabbit; Invitrogen), p214 (Ser-214, rabbit; Invitrogen), 
pS262 (Ser-262, rabbit; Invitrogen), PHF1 (mouse; a generous gift of   
P. Davies, Albert Einstein College of Medicine, Bronx, NY), and Tau-1 (mouse; 
a generous gift of L. Binder, Northwestern University, Chicago, IL). Also 
used were anti-GFP (rabbit; Invitrogen), anti-FLAG (M5), anti-tubulin (mouse, 
DM1A;  rat,  YL1/2),  anti-acetylated  tubulin  (mouse;  6-11B-1),  anti-actin 
(mouse, JLA20; EMD) and anti-AnxA2 (mouse, annexin II [H-5], Santa Cruz 
Biotechnology; mouse, HH7 [Thiel et al., 1992]). As secondary antibodies, 
peroxidase-, Cy3-, and Alexa Fluor 488–conjugated anti–mouse and anti–
rabbit antibodies (Jackson ImmunoResearch Laboratories, Inc.) were used.
Construction of expression vectors, transfections, and lentiviral infections
Eukaryotic expression plasmids for fetal (352 aa) or adult (441 aa) human 
tau with amino-terminally fused FLAG, mRFP, EGFP, and PAGFP tags were 
constructed in pRc/cytomegalovirus (CMV)-based expression vectors (Invit-
rogen) containing a CMV promoter and kanamycin and neomycin resis-
tance genes. PAGFP was constructed from EGFP by changing the codons 
L64F, T65S, V163A, and T203H by site-directed mutagenesis with primers 
as described previously (Patterson and Lippincott-Schwartz, 2002). The 
vector pSETbmRFP was provided by R.Y. Tsien (University of California, 
San Diego, La Jolla, CA). To produce R406W tau constructs, R406 was 
mutated  to  W  by  site-directed  mutagenesis  of  the  respective  codon.   
Annexin A2 amino-terminally fused to PAGFP was cloned into the lentiviral 
vector L26FSy(1.1)GW (provided by P. Osten, Northwestern University, 
Chicago, IL), which contains the neuron-specific promoter Synapsin I 
(Dittgen et al., 2004). Sequences that were introduced by PCR were veri-
fied by DNA sequencing.
Transfections  of  PC12  cells  were  performed  with  Lipofectamine 
2000 (Invitrogen) essentially as described previously (Fath et al., 2002). 
For generation of stable lines, individual clones were selected in the pres-
ence of 500 µg/ml Geneticin, then picked and propagated in serum-DME 
supplemented with 250 µg/ml Geneticin on collagen-coated culture dishes 
as described previously (Brandt et al., 1995). For each construct, several 
independent clonal lines were selected that expressed comparable levels 
of the protein.
For production of lentivirus, human embryonic kidney cells 293FT 
(Invitrogen) were transfected with the expression vector and two helper 
plasmids using TransIT-293 transfection reagent (Mirus Bio LLC). Viral par-
ticles from the supernatant were concentrated by ultracentrifugation and 
used to infect PC12 cells.
Cell culture
PC12  cells  were  cultured  in  serum-DME  as  described  previously  (Fath   
et  al.,  2002).  For  stable  lines,  250  µg/ml  Geneticin  was  included  in   
the  medium.  Undifferentiated  cells  were  plated  on  35-mm  polylysine-   
and collagen-coated glass-bottom culture dishes (MatTek Corporation) at   
10
3 cells/cm
2 and cultured in DME with 1% (vol/vol) serum. Cells were 
flattened by addition of 100 ng/ml 7S mouse NGF (Alomone Laborato-
ries) for 1–2 d. For neuronal differentiation, NGF treatment was extended 
to 4–6 d and the medium was changed every 2–3 d. Before imaging, the 
medium was exchanged against the same medium containing DME with-
out Phenol red. For some experiments, cells were treated with 10 nM 
BAPTA/AM (EMD) for 30 min before imaging.
Primary cortical cultures were prepared from cerebral cortices of 
mouse embryos (day 15–17 of gestation) and cultured as described previ-
ously  (Leschik  et  al.,  2007).  The  cultures  were  obtained  by  breeding 
C57BL/6 mice. Cells were plated at 5 × 10
4 cells/cm
2 on polylysine- and 
laminin-coated coverslips.
Immunocytochemistry
Immunocytochemistry after fixation with 4% paraformaldehyde and a com-
bined NP-40 detergent extraction–fixation procedure to reveal cytoskeletal 
association were performed as described previously (Brandt et al., 1995). 
Fluorescence  microscopy  was  performed  using  a  dry  20×  (NA  0.45; 
ELWD), an oil-immersion 60× (NA 1.4), and an oil-immersion 100× (NA 1.3) JCB • VOLUME 192 • NUMBER 4 • 2011   660
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